Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer

Sheema Khan, Mara C. Ebeling, Neeraj Chauhan, Paul A. Thompson, Rishi K. Gara, Aditya Ganju, Murali M. Yallapu, Stephen W. Behrman, Haotian Zhao, Nadeem Zafar, Man Mohan Singh, Meena Jaggi, Subhash C. Chauhan

Research output: Contribution to journalArticle

49 Scopus citations

Abstract

The management of pancreatic ductal adenocarcinoma (PDAC) is extremely poor due to lack of an efficient therapy and development of chemoresistance to the current standard therapy, gemcitabine. Recent studies implicate the intimate reciprocal interactions between epithelia and underlying stroma due to paracrine Sonic hedgehog (SHH) signaling in producing desmoplasia and chemoresistance in PDAC. Herein, we report for the first time that a nonsteroidal drug, ormeloxifene, has potent anticancer properties and depletes tumor-associated stromal tissue by inhibiting the SHH signaling pathway in PDAC. We found that ormeloxifene inhibited cell proliferation and induced death in PDAC cells, which provoked us to investigate the combinatorial effects of ormeloxifene with gemcitabine at the molecular level. Ormeloxifene caused potent inhibition of the SHH signaling pathway via downregulation of SHH and its related important downstream targets such as Gli-1, SMO, PTCH1/2, NF-κB, p-AKT, and cyclin D1. Ormeloxifene potentiated the antitumorigenic effect of gemcitabine by 75% in PDAC xenograft mice. Furthermore, ormeloxifene depleted tumor-associated stroma in xenograft tumor tissues by inhibiting the SHH cellular signaling pathway and mouse/human collagen I expression. Xenograft tumors treated with ormeloxifene in combination with gemcitabine restored the tumor-suppressor miR-132 and inhibited stromal cell infiltration into the tumor tissues. In addition, invasiveness of tumor cells cocultivated with TGFb-stimulated human pancreatic stromal cells was effectively inhibited by ormeloxifene treatment alone or in combination with gemcitabine. We propose that ormeloxifene has high therapeutic index and in a combination therapy with gemcitabine, it possesses great promise as a treatment of choice for PDAC/pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)2292-2304
Number of pages13
JournalCancer Research
Volume75
Issue number11
DOIs
StatePublished - Jun 1 2015

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer'. Together they form a unique fingerprint.

  • Cite this

    Khan, S., Ebeling, M. C., Chauhan, N., Thompson, P. A., Gara, R. K., Ganju, A., Yallapu, M. M., Behrman, S. W., Zhao, H., Zafar, N., Singh, M. M., Jaggi, M., & Chauhan, S. C. (2015). Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer. Cancer Research, 75(11), 2292-2304. https://doi.org/10.1158/0008-5472.CAN-14-2397